Childhood Acute Lymphoblastic Leukemia in Complete Remission Active Not Recruiting Phase 2 Trials for Ofatumumab (DB06650)

IndicationStatusPhase
DBCOND0080800 (Childhood Acute Lymphoblastic Leukemia in Complete Remission)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01363128Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTreatment